The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Arteriosclerosis Obliterans

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Arteriosclerosis Obliterans

 

High impact information on Arteriosclerosis Obliterans

 

Chemical compound and disease context of Arteriosclerosis Obliterans

 

Biological context of Arteriosclerosis Obliterans

 

Anatomical context of Arteriosclerosis Obliterans

 

Gene context of Arteriosclerosis Obliterans

 

Analytical, diagnostic and therapeutic context of Arteriosclerosis Obliterans

References

  1. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Morishita, R., Nakamura, S., Hayashi, S., Taniyama, Y., Moriguchi, A., Nagano, T., Taiji, M., Noguchi, H., Takeshita, S., Matsumoto, K., Nakamura, T., Higaki, J., Ogihara, T. Hypertension (1999) [Pubmed]
  2. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis. Kawano, M., Kuroda, Y., Terao, M., Yaginuma, T., Kawakami, M., Kanazawa, Y. Clin. Chim. Acta (2002) [Pubmed]
  3. Lack of effect of ischemia and dipyridamole on prostacyclin production in arteriosclerosis obliterans. Viinikka, L., Kärkölä, P., Pokela, R., Ylikorkala, O. Prostaglandins (1981) [Pubmed]
  4. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans. Horváth, M., Varsányl, M., Jovanovich, N., Romics, L., Gerö, S. Allergologia et immunopathologia. (1990) [Pubmed]
  5. The usefulness of dipyridamole thallium-201 single photon emission computed tomography for predicting perioperative cardiac events in patients undergoing non-cardiac vascular surgery. Chen, T., Kuwabara, Y., Tsutsui, H., Sasaki, M., Nakagawa, M., Koga, H., Kaneko, K., Komori, K., Masuda, K. Annals of nuclear medicine. (2002) [Pubmed]
  6. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Szczeklik, A., Nizankowski, R., Skawinski, S., Szczeklik, J., Gluszko, P., Gryglewski, R.J. Lancet (1979) [Pubmed]
  7. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Yamakawa, J., Takahashi, T., Itoh, T., Kusaka, K., Kawaura, K., Wang, X.Q., Kanda, T. Diabetes Care (2003) [Pubmed]
  8. Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Matsumoto, K., Miyake, S., Yano, M., Ueki, Y., Yamaguchi, Y., Akazawa, S., Tominaga, Y. Diabetes Care (1997) [Pubmed]
  9. Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans. Grodzińska, L., Basista, M., Kedzior, A., Korbut, R., Kostka-Trabka, E., Gryglewski, R. Thromb. Haemost. (1983) [Pubmed]
  10. Enhancement of nitric oxide production after arterial reconstruction in patients with arteriosclerosis obliterans. Komori, K., Matsumoto, T., Ishida, M., Kuma, S., Yonemitsu, Y., Eguchi, D., Sugimachi, K. J. Vasc. Surg. (1997) [Pubmed]
  11. Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts. Esato, K., Kubo, Y., Yasuda, K., Shigematsu, H., Iwai, T., Ishimaru, S., Uchida, H., Ishii, K. Am. J. Surg. (1998) [Pubmed]
  12. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. Jouve, R., Rolland, P.H., Delboy, C., Mercier, C. Am. Heart J. (1984) [Pubmed]
  13. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Nakamura, K., Kariyazono, H., Masuda, H., Sakata, R., Yamada, K. Blood Coagul. Fibrinolysis (2001) [Pubmed]
  14. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Nomura, S., Inami, N., Iwasaka, T., Liu, Y. Platelets (2004) [Pubmed]
  15. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. Novo, S., Alaimo, G., Abrignani, M.G., Giordano, U., Avellone, G., Pinto, A., Adamo, L., Cutietta, A., Indovina, A., Strano, A. International journal of clinical pharmacology research. (1986) [Pubmed]
  16. Some haemorheological factors in patients with arteriosclerosis obliterans after treatment of trental. Chyzy, R., Lukjan, H., Rość, D., Bielawiec, M., Sawicka, J. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. (1987) [Pubmed]
  17. Microcirculatory characteristics in patients with Buerger's disease. Nishikimi, N., Sakurai, T., Shionoya, S., Oshima, M. Angiology. (1992) [Pubmed]
  18. Plasma antioxidant potency and serum copper levels in atherosclerosis. Dembińska-Kieć, A., Zmuda, A., Bieroń, K., Grodzińska, L., Basista, M., Kedzior, A., Kostka-Trabka, E. Polish journal of pharmacology and pharmacy. (1985) [Pubmed]
  19. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Kawano, T., Saito, T., Yasu, T., Saito, T., Nakamura, T., Namai, K., Tamemoto, H., Kawakami, M., Saito, M., Ishikawa, S.E. Metab. Clin. Exp. (2005) [Pubmed]
  20. Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. Yamakawa, J., Takahashi, T., Saegusa, S., Moriya, J., Itoh, T., Kusaka, K., Kawaura, K., Wang, X.Q., Kanda, T. J. Int. Med. Res. (2004) [Pubmed]
  21. Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. Noguchi, M., Eishi, K., Yamachika, S., Hazama, S. Heart and vessels. (2004) [Pubmed]
  22. Complement activation by vascular prostheses and its role in progression of arteriosclerotic lesions. Miyauchi, M., Shionoya, S. Angiology. (1988) [Pubmed]
  23. Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy. Okada, S., Ogino, Y., Ichiki, K., Tanokuchi, S., Ishii, K., Hamada, H., Ota, Z., Hiraki, Y. J. Int. Med. Res. (1991) [Pubmed]
  24. Usefulness of the Symphony Nitinol Stent for arteriosclerosis obliterans. Kinoshita, Y., Suzuki, T., Hosokawa, H., Yokoya, K. Circ. J. (2002) [Pubmed]
  25. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Mii, S., Mori, A., Sakata, H., Nakayama, M., Tsuruta, H. Angiology. (1998) [Pubmed]
 
WikiGenes - Universities